Industry news

06 March 2018

Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2017.

06 March 2018

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“TOPAZ”) of suprachoroidal CLS-TA used with an intravitreally administered anti-VEGF agent (“intravitreal anti-VEGF agent”) for the treatment of macular edema associated with Retinal Vein Occlusion (“RVO”).

The Innovation Distinction: Biopharma's Reputational Pass

Michelle Maskaly / Pharmaceutical Executive

While traditional pharmaceutical companies are taking a reputational hit, biotech organizations, for the most part, are getting a public-perception pass—for now.  Whether or not it’s fair, or accurate, in general, the public views biotech companies as cutting edge, holding the cure to some of the world’s most debilitating diseases, and as alternatives to the traditional pharma enterprise, and its characterization by some as greedy, outdated, and only caring about making money.

"Value" Will Define the Next Year

Cassandra Sinclair / Pharmaceutical Executive

Digital transformation has been the hot topic of 2017—especially in pharma—filled with conversations around the optimization of tech stacks, DAM (digital asset management) amplification, and ecommerce solutions. The need for transformation had been put into overdrive by market forces like the Triple Aim, changing demographics and the proliferation of data and technology. All increasing pressure on traditional industry players to deliver customer-centric engagement models.

05 March 2018

Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2017. In addition, the Company provided a clinical and business update. As of December 31, 2017, Syndax had $133.2 million in cash, cash equivalents and short-term investments.

05 March 2018

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis. 

Syneos Health 2018 Trends Forecast

Pharmaceutical Executive

Syneos Health released its inaugural Commercial Trends Forecast. The report identifies trends in biopharmaceutical commercialization—from the frontlines of drug development to patient engagement and next-generation care.

12 Life Sciences Trends to Look Forward to in 2018

Pharmaceutical Executive

In 2017, life sciences companies took important steps to advance their business processes and drive greater efficiencies in drug development and commercial operations. The industry will embrace transformation initiatives at a faster pace in 2018, across multiple functional areas, including commercial, clinical, regulatory, and quality. In product development, companies are focused on streamlining end-to-end processes to speed time to market and maintain compliance. For commercial teams, driving smarter engagement with customers remains a core focus as they launch more specialized products.

Digital Innovation: Staying Ahead of the Curve

Kal Patel, M.D. / Pharmaceutical Executive

Companies in every industry are tapping into digital innovation to increase revenue, reduce costs and better serve customers. The pharmaceutical industry should be no exception. To date, the healthcare industry has contributed advances to telemedicine, robotic assistance and real-time monitoring devices among other technologies. However, the pace of pharma’s digital technology adoption remains slow due to the fear of escalating cybersecurity and privacy challenges, strict federal and state regulations and a need for more digital expertise.

Showdown Approaching on European Research Incentives

Pharmaceutical Executive

What goes around comes around in keeping competitors away from profitable medicines, just as in anything else. And now Europe is locked in a battle over whether to roll back some of the protection it gave drug innovators in the last century.